Cassava Sciences, Inc. SAVA 深 沪
等待开盘 04-01 09:30:00 美东时间
2.38
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.38
- 总市值 1.15亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.15
- 委 比 0.00%
- 总股本 4830.79万
- 历史最高 146.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.00
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cassava Sciences GAAP EPS of -$0.26
Cassava Sciences press release (FLNA): Q4 GAAP EPS of -$0.26. Net cash used in operations was $32.3 million in 2025, consistent with previous guidance. The Company met cash guidance for year-end 2025,...
03-13 03:05
Cassava Sciences Changes Name To Filana Therapeutics, Ticker To FLNA, Effective March 11
Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand
03-10 20:14
Cassava Sciences to rebrand to Filana Therapeutics
Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders. The c...
03-10 20:09
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
Cassava Sciences更名为Filana Therapeutics，专注于开发调节filamin A蛋白的药物以治疗TSC相关癫痫，并将在纳斯达克以FLNA代码交易。公司希望通过这一战略聚焦，为患者及其家庭带来更多治疗选择。
03-10 12:00
Cassava Sciences Says U.S. DOJ Fraud Section Closes Its Inquiry Into The Company Regarding Allegations Of Research Misconduct
Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis
02-19 21:03
Cassava Announces Closure of U.S. Department of Justice Investigation
Cassava Sciences announced that the U.S. Department of Justice has closed its investigation into allegations of research misconduct, with the related indictment dismissed in October 2025. The company had previously settled with the SEC in September 2024, paying a penalty without admitting fault. CEO Richard J. Barry stated that the resolutions reinforce stakeholder trust and the company remains focused on developing treatments for TSC-related epi...
02-19 13:00
2025全球十大失败临床试验
（来源：抗体圈） FierceBiotech每年梳理年度临床实验失败案例。2025年的这份榜单依旧偏向行业头部药企，也反映出一个现实，绝大多数高风险的中晚期...
02-13 12:22
Cassava Sciences Announces Publication Of Article Phase 3 Randomized Clinical Trials Of Simufilam In Mild-To-Moderate Alzheimer's Disease In Upcoming Issue Of JPAD
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and
01-13 21:04
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
Cassava Sciences announced the publication of a paper detailing results from its Phase 3 RETHINK-ALZ and REFOCUS-ALZ trials for simufilam in mild-to-moderate Alzheimer’s disease. While the studies did not meet pre-specified endpoints, exploratory analyses showed potential benefits in mild subgroups. Simufilam demonstrated slower cognitive decline in mild Alzheimer’s patients compared to placebo in REFOCUS-ALZ and pooled analyses. The company has ...
01-13 13:00
期权扫描 | 科技股普遍获看好！谷歌市值升至美股第2，多张Call单飙升；英特尔期权成交放量超2倍
科技股普遍获看好！谷歌市值升至美股第2，看涨期权占比逾7成，多张Call单大涨逾300%；英特尔股价大涨6%，期权成交放量超2倍，看涨期权占比近8成>>
01-08 17:57
